×

Do you want to link to other external websites and leave Amgen.com.au?

You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for, and exercises no control over the organisation, views, or information contained on the server or site which you will be accessing. The information contained might not comply with the Australian regulatory environment.

×

Do you want to link to other websites and leave Amgen.com.au?

You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.

OUR COMMITMENT TO RESEARCH AND DEVELOPMENT

Through its significant clinical presence, Amgen Australia conducts on average two First in Human (FIH) studies every year and almost half of its clinical trial activity is in early phase research (PI-PII). In 2015, Amgen conducted 62 different studies at 347 sites across Australia and New Zealand, involving 1,645 patients’ trialling Amgen’s innovative medicines.

Amgen Australia contributes disproportionately to the global clinical trial effort by being in the top ten countries for active clinical studies and in the top five for interventional studies. At any one time, Amgen Australia is involved in approximately 25% of interventional studies in the global clinical trial program.

AmgenTrials.com is dedicated to bringing information about Amgen's clinical trials to patients and healthcare communities. Content reflected on AmgenTrials.com is currently updated on a weekly basis.